Work

O-151 Phase II study of anatumomab mafenatox (ABR-214936) in advanced NSCLC: Results of a multi-institutinal open label repeat dose trial with patient-specific dose escalation

Year: 2003

Type: conference-abstract

Source: Lung Cancer

DOI: 10.1016/s0169-5002(03)91809-5

Authors: Corey J. Langer, R. Katherine Alpaugh, Francisco Robert, L.M. Weiner, Joan Schiller, M. Kopreski, Andre Rogatko, Goran Forsberg

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2028185999

Cites:

Cited by: 1

Related to: 10